How can Life Science Technology Providers Support the Pharmaceutical Industry in the Transition Toward More Digitally Connected Operations?

News
Published: June 24, 2024 Last updated: June 26, 2024

GBI’s Amita Quadros, Ph.D., Vice President of Commercial Operations participated in this Pharma Almanac’s roundtable discussion.

The topic of discussion was “How can Life Science Technology Providers Support the Pharmaceutical Industry in the Transition Toward More Digitally Connected Operations?”:

Amita Quadros, Ph.D., Vice President of Commercial Operations, GBI

Life sciences technology providers can support the pharmaceutical industry in transitioning toward more digitally connected operations in several ways: digital Transformation in the pharma industry provides solutions to pharmaceutical companies, such as more flexible manufacturing processes and improved speed to market. Other aspects include real-time monitoring of manufacturing processes and supply chain optimization, thereby enhancing efficiency and compliance with regulatory requirements. Through AI and machine learning tools, life sciences technology providers can help pharmaceutical companies analyze vast amounts of data generated from clinical trials, manufacturing processes, etc. This information helps identify patterns, predict outcomes, and optimize processes from drug discovery to clinical trials and commercialization. Data integrity and intellectual property are two other critical aspects for pharma companies, and companies partnering with them should ensure they have systems in place to protect this information, including confidentiality, by developing software solutions that streamline regulatory compliance processes per regulations such as the FDA’s 21 CFR Part 11. Overall, life science technology providers enable pharmaceutical companies to harness the power of digitization to drive innovation, accelerate drug development, improve operational efficiency, and deliver better outcomes for patients.

Click here to read the article and learn more.